Glenmark Pharmaceuticals Limited has informed the Exchange regarding Change in Auditors of the company.
GLENMARK · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Glenmark Pharmaceuticals' board approved the transfer of its Consumer Care business to a newly created wholly owned subsidiary, Glenmark Consumer Care Limited, for about ₹240.40 crore. The Consumer Care segment contributed ₹514.7 crore in turnover (5.6% of standalone revenue) and ₹249.2 crore in net worth for FY25. The board appointed Ms. Patricia Andrews as a Non-Executive Independent Director for 5 years; she brings pharma and biotech leadership experience from US-listed companies. Walker Chandiok & Co. LLP was appointed as the new Statutory Auditor for 5 years, and Rauthan & Associates LLP as Secretarial Auditor for 5 years. The 47th Annual General Meeting has been scheduled for September 26, 2025.
The business transfer sharpens strategic focus on the core pharma business while letting the high-growth Consumer Care unit operate independently. The auditor and director changes are routine governance updates requiring shareholder approval at the upcoming AGM, with no disruption indicated.